400 related articles for article (PubMed ID: 29143176)
1. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J
Target Oncol; 2017 Dec; 12(6):757-774. PubMed ID: 29143176
[TBL] [Abstract][Full Text] [Related]
2. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
Chandrasekharan C
Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
[TBL] [Abstract][Full Text] [Related]
3. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
[TBL] [Abstract][Full Text] [Related]
4. Update in the Therapy of Advanced Neuroendocrine Tumors.
Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
Khagi S; Saif MW
JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
[TBL] [Abstract][Full Text] [Related]
6. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
8. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
9. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):10-14. PubMed ID: 28654024
[No Abstract] [Full Text] [Related]
12. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States.
Jiao X; Pulgar S; Boyd M; Braiteh F; Mirakhur B; Pitman Lowenthal S; Fox P; Frytak J; Cox D; Paulson AS
Pancreas; 2018 Feb; 47(2):173-182. PubMed ID: 29206668
[TBL] [Abstract][Full Text] [Related]
14. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
16. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].
Auernhammer CJ; Spitzweg C; Böck S; Knösel T; Bartenstein P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1390-1395. PubMed ID: 31594011
[TBL] [Abstract][Full Text] [Related]
17. G3 GEP NENs category: are basic and clinical investigations well integrated?
Milione M; Fazio N
Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
19. Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Iyer R
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):3-10. PubMed ID: 28654023
[No Abstract] [Full Text] [Related]
20. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
